| 38 0.73 (1.96%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.15  |
1-year : | 60.91 |
| Resists | First : | 44.65 |
Second : | 52.15 |
| Pivot price | 37.05  |
|||
| Supports | First : | 36.21 |
Second : | 31 |
| MAs | MA(5) : | 36.03 |
MA(20) : | 37.42 |
| MA(100) : | 43.19 |
MA(250) : | 33.28 |
|
| MACD | MACD : | -1.6 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 69.3 |
D(3) : | 56.1 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 48.59 | Low : | 11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BLTE ] has closed below upper band by 40.4%. Bollinger Bands are 33.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 38.49 - 38.63 | 38.63 - 38.75 |
| Low: | 35.64 - 35.81 | 35.81 - 35.96 |
| Close: | 37.73 - 37.97 | 37.97 - 38.19 |
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Thu, 25 Apr 2024
Belite Bio Announces $25 Million Registered Direct Offering - Yahoo Finance
Thu, 18 Apr 2024
Belite Bio (NASDAQ:BLTE) Trading Up 6.7% - MarketBeat
Fri, 12 Apr 2024
Belite Bio (NASDAQ:BLTE) Stock Price Down 5.5% - MarketBeat
Fri, 12 Apr 2024
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 34.3% in March - MarketBeat
Wed, 10 Apr 2024
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect? - Yahoo Finance
Wed, 20 Mar 2024
We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 60.2 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 39 (K) |
| Shares Short P.Month | 49 (K) |
| EPS | -1.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.5 % |
| Return on Equity (ttm) | -48 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -31.94 |
| PEG Ratio | 0 |
| Price to Book value | 12.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -37.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|